Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.
Formulary Watch
Latest News
All News
Advertisement
Wynzora is a cream-based, fixed dose combination of calcipotriene and betamethasone for topical treatment of psoriasis.
This is being done in coordination with the FDA to address the shortage created by the recall of Chantix. UPDATE: Pfizer has expanded its recall of Chantix from nine lots to 12 lots.
The company’s stock began dropping on Tuesday with analyst expectation the FDA will issue a Complete Response Letter for tenapanor, its chronic kidney disease therapy.
Eight out of 10 covered U.S. commercial lives now have access to the H. pylori therapy.
This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.
Vaxneuvance is approved for 15 serotypes, including those that are major causes of disease.
Current drug shortages based on FDA data, prepared by Formulary Watch.
FDA staff raised safety concerns ahead of the advisory panel hearing.
Merck has submitted the data from the study KEYNOTE-522 to the FDA for review.
Advertisement
The first generic of the high-dose intravenous iron, a generic of Feraheme, is now available.
Committee members raised safety concerns about FibroGen/AstraZeneca’s oral therapy roxadustat.
Several large payers are waiting on results from the National Coverage Determination.
After generic entry, Zytiga’s market share fell to about 14% and monthly net sales across the entire market fell 85%.
New analysis suggests that even with rebates, the new Alzheimer’s therapy could have implications for Medicaid drug spending.
An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.
A permanent code is expected in the third quarter of 2021.
The first generic equivalent of the HIV therapeutic is now available.
The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.
The new indication provides a subcutaneous option for multiple myeloma that can be administrated in minutes, rather than hours.
The review will determine whether there should be a national Medicare coverage policy for the Alzheimer’s therapy.
Jardiance lowered risk of hospitalization from acute kidney injury but increased risk of hospitalized from diabetic ketoacidosis compared with a DPP4 inhibitor in one interim analysis.
Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.
While the risk of exposure is low, it presents a severe hazard.
This is part of a larger effort by President Joe Biden to promote competition in the American economy.
The specialty pharmacy is licensed in all 50 states.
Advertisement
Advertisement